Sol-Gel Technologies Ltd.
NASDAQ:SLGL · NASDAQ Global Market
-$1.86 today
Vol 0.01M · Avg 0.04M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:SLGL · Revenue to Net Income
Key Ratios
Analysis
$18.5M of revenue converted into -$1.0M of net income for the selected period. Gross margin is 100.0% and net margin is -1324.6%, showing how much revenue survives after costs and taxes. EPS is $-0.34, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $19.4M +68.0% | $11.5M +642.5% | $1.6M -60.0% | $3.9M -87.6% | $31.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 -100.0% | $233.0K -31.9% | $342.0K -97.3% | $12.7M -37.8% | $20.4M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $19.4M +71.5% | $11.3M +151.4% | -$22.0M -149.9% | -$8.8M -180.8% | $10.9M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 100.0% +2.0pp | 98.0% +1512.8pp | -1414.9% -1188.3pp | -226.6% -261.4pp | 34.8% | 9.8% | 28.9% | 38.3% |
| Research & Development | $22.8M +28.1% | $17.8M -24.4% | $23.5M +85.6% | $12.7M -37.8% | $20.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $4.2M -27.4% | $5.7M -22.0% | $7.4M -1.0% | $7.4M -11.9% | $8.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $26.9M +15.5% | $23.3M +218.7% | $7.3M -1.7% | $7.4M -6.1% | $7.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $109.0K -53.2% | $233.0K -31.9% | $342.0K -39.1% | $562.0K -36.1% | $880.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$7.4M +28.2% | -$10.3M +64.3% | -$29.0M -84.7% | -$15.7M -508.0% | $3.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -38.3% +51.4pp | -89.7% +1774.1pp | -1863.8% -1459.9pp | -403.9% -416.2pp | 12.3% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$7.5M +37.3% | -$12.0M +59.0% | -$29.3M -80.4% | -$16.2M -648.0% | $3.0M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -38.9% +65.2pp | -104.1% +1781.7pp | -1885.8% -1467.4pp | -418.3% -427.8pp | 9.5% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.4M -1.6% | $1.4M -30.6% | $2.1M +56.5% | $1.3M +414.0% | $257.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.4M -1.6% | $1.4M -30.6% | $2.1M +56.5% | $1.3M +414.0% | $257.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$6.1M +42.1% | -$10.6M +61.2% | -$27.2M -82.5% | -$14.9M -563.3% | $3.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -31.6% +60.1pp | -91.7% +1661.1pp | -1752.8% -1368.5pp | -384.3% -394.6pp | 10.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$6.1M +42.1% | -$10.6M +61.2% | -$27.2M -82.5% | -$14.9M -563.3% | $3.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | -31.6% +60.1pp | -91.7% +1661.1pp | -1752.8% -1368.5pp | -384.3% -394.6pp | 10.3% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 -478.9% | -$0 +62.4% | -$1 -55.4% | -$1 -146.4% | $1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 -478.9% | -$0 +62.4% | -$1 -55.4% | -$1 -564.3% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $2.8M -90.0% | $27.9M +2.8% | $27.1M +17.1% | $23.1M +0.3% | $23.1M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $2.8M -90.0% | $27.9M +2.8% | $27.1M +17.1% | $23.1M -1.9% | $23.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Oramed Pharmaceuticals Inc.
NASDAQ:ORMP
$158.38M
Coya Therapeutics, Inc.
NASDAQ:COYA
$86.31M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Tiziana Life Sciences Ltd
NASDAQ:TLSA
$65.37M
Clene Inc.
NASDAQ:CLNN
$60.20M
OKYO Pharma Limited
NASDAQ:OKYO
$58.32M
Anebulo Pharmaceuticals, Inc.
ANEB
$19.37M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SLGL generate?
Sol-Gel Technologies Ltd. (SLGL) reported $19.39M of revenue in fiscal 2025.
Is SLGL profitable?
Sol-Gel Technologies Ltd. (SLGL) reported -$6,127,000.00 of net income, with a net margin of -31.6%.
Explore More
Continue the stock analysis
Jump to another research area for this company.